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Oxytocin is frequently used worldwide. Some of its adverse
effects are well known, but bronchospasm and laryngeal
stridor as anaphylactoid reactions have not yet been
reported.
Oxytocin is a synthetically prepared hormone that stimulates
contractions of uterine smooth muscle and it is used for
induction and augmentation of labor as well as in abortions.
Adverse effects reported with oxytocin include reflex
tachycardia, hypotension, electrocardiographic changes,
increased cardiac output, myocardial infarction, alteration in
fetal heart rate, seizures, headache, memory impairment,
cerebrospinal bleeding, hyponatremia, syndrome of
inappropriate antidiuretic hormone secretion, nausea and
vomiting, uterine rupture, neonatal hyperbilirubinemia, and
anaphylaxis [1]. To our knowledge, bronchospasm and
laryngeal stridor occur very rarely in oxytocin anaphylaxis.
A 41-year-old woman was admitted to our intensive care unit
after having a septic abortion in the 18th week of pregnancy.
This was her second gestation (the first culminating in a
cesarean section). After abortion she presented with septic
shock, oligoanuria, consumption coagulopathy, and
respiratory insufficiency.
She was first treated intravenously with crystalloids, colloids,
inotropics, furosemide perfusion, empirical antibiotics (i.e.
cefotaxime, metronidazol, and doxycycline), and frozen fresh
plasma. She was anticoagulated with low-molecular-weight
heparin. She also received an intravenous infusion of oxytocin at
40mU/min. Just after infusion, she showed signs of tachypnea,
bronchospasm, and laryngeal stridor. We immediately started
treatment with β2 agonist drugs. Thirty minutes later the patient
showed slight improvement, but symptoms only disappeared
when oxytocin was withdrawn. The patient’s condition improved
rapidly and recovery was uneventful. She had had no previous
allergic reactions or asthma.
Anaphylactoid reactions to oxytocin have been described in
the literature [2]. Some of the clinical presentations of
oxytocin anaphylactoid reactions described include patchy
erythema, hypotension, bronchospasm, and reduced oxygen
saturation [3,4]. A case of life-threatening respiratory distress
following the use of oxytocin during cesarean delivery was
reported in 1994; the authors of that report also suggested
that this was an anaphylactoid reaction to synthetic oxytocin
[5]. In the case described here, the close temporal
relationship between oxytocin administration and
bronchospasm and laryngeal stridor, and the rapid abatement
of symptoms following oxytocin withdrawal suggest that the
relation was a causal one and that the patient had suffered
an anaphylactoid reaction.
Competing interests
None declared.
References
1. Batagol R, Drugdex Editorial Staff: Oxytocin: drug evaluation. In
Drugdex Information System, vol 104. Englewood, CO:
Micromedex Inc.; 2000.
2. Spears FD, Liu DWH: Anaphylactoid reaction to syntocinon?
Anaesthesia 1994, 49:550-551.
3. Slater RM, Bowles BJM, Pumphrey RSM: Anaphylactoid reac-
tion to oxytocin in pregnancy. Anaesthesia 1985, 40:655-656.
4. Emmott RS: Recurrent anaphylactoid reaction during cae-
sarean section [letter]. Anaesthesia 1990, 45:62.
5. Morriss WW, Lavies NG, Anderson SK, Southgate HJ: Acute res-
piratory distress during caesarean section under spinal
anaesthesia. A probable case of anaphylactoid reaction to
Syntocinon. Anaesthesia 1994, 49:41-43.
Letter
Bronchospasm and laryngeal stridor as an adverse effect of
oxytocin treatment
David Cabestrero1, Carmen Pérez-Paredes1, Ramón Fernández-Cid2 and Miguel A Arribas1
1Staff Specialist, Critical Care Unit, Hospital Verge del Toro, Mahón (Menorca), Spain
2Director of Intensive Care, Critical Care Unit, Hospital Verge del Toro, Mahón (Menorca), Spain
Correspondence: David Cabestrero, cabestrero@saludalia.com
Published online: 10 July 2003 Critical Care 2003, 7:392 (DOI 10.1186/cc2348)
This article is online at http://ccforum.com/content/7/5/392
© 2003 BioMed Central Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X)